Loading
Premier, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Feb 2016.
Premier, Inc.: what insiders have been doing
Every trade that managers of Premier, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 17 filings signed by 15 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Over the last twelve months, not one insider purchase of Premier, Inc. stock was filed. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,813 companies, median 19 filings), a count of 17 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 1 purchase and 40 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 June 2025), the company reported revenue of 1.01 bn USD and net income of 30.8 m USD, with a dividend of 0.21 USD per share.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
182
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€8M
40 ops. · all time
Who traded when
BuySaleJohn T. Bigalke4 sales
Andy Brailo2 sales
David L. Klatsky2 sales
Helen M. Boudreau2 sales
Michael J. Alkire2 sales
Leigh Anderson1 sale
Analyst consensus: bullish or bearish?
Analysts rate Premier, Inc. Hold (neutral), based on 1 analysts. Average price target: US$28.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,411 of 24,148 companies
59.1
score / 100
Value64
Quality54
FCF yld18%
Earn yld1.1%
EV/EBITDA9.0x
ROE0.9%
Gross mgn73%
Net mgn2.0%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
US$49.97
Analyst consensus
1 analystsHold
US$28.25Target US$28.25(-43%)US$28.25
Income statement
RevenueUS$1B
Gross profitUS$743.4M73% margin
EBITDAUS$232.9M23% margin
Net incomeUS$20.3M2.0% margin
Valuation
PER (trailing)293.9x
PER (forward)17.4x
P/Book1.5x
Beta0.61
Balance sheet & cash
Market capUS$1.8B
Total debtUS$282M
Free Cash FlowUS$318.8M
Debt / Equity21%
Profitability & ownership
ROE0.9%
ROA3.0%
% insiders0.9%
% institutions85.8%
Last declaration on 26 November 2025
Declarations182 total
22,535 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-299023:0
52,708 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-299017:0
161,464 shares@ US$28.2590.5% of flowClass A Common StockSEC:0001193125-25-299012:0
529,432 shares@ US$28.2556.7% of flowClass A Common StockSEC:0001193125-25-299002:0
79,817 shares@ US$28.2567.5% of flowClass A Common StockSEC:0001193125-25-298999:0
45,190 shares@ US$28.2595.4% of flowClass A Common StockSEC:0001193125-25-298927:0
78,693 shares@ US$28.2564.4% of flowClass A Common StockSEC:0001193125-25-298914:0
51,938 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-298903:0
42,450 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-298891:0
42,450 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-298887:0
42,450 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-298882:0
35,349 shares@ US$28.25100.0% of flowClass A Common StockSEC:0001193125-25-298877:0
21,033 shares@ US$28.2567.2% of flowClass A Common StockSEC:0001193125-25-298855:0
18,668 shares@ US$28.2568.2% of flowClass A Common StockSEC:0001193125-25-298830:0
27,536 shares@ US$28.2588.1% of flowClass A Common StockSEC:0001193125-25-298806:0
17,026 shares@ US$28.179.5% of flowClass A Common StockSEC:0001193125-25-277429:0
1,260 shares@ US$28.122.6% of flowClass A Common StockSEC:0001193125-25-262761:0
5,581 shares@ US$26.294.2% of flowClass A Common StockSEC:0000950170-25-113467:0
6,521 shares@ US$25.794.8% of flowClass A Common StockSEC:0001995357-25-000007:0
1,137 shares@ US$25.793.3% of flowClass A Common StockSEC:0001791350-25-000004:0
1,319 shares@ US$25.851.0% of flowClass A Common StockSEC:0001677162-25-000008:0
2,622 shares@ US$25.141.9% of flowClass A Common StockSEC:0001995357-25-000005:0
1,453 shares@ US$25.141.0% of flowClass A Common StockSEC:0001995357-25-000005:1
16,334 shares@ US$25.141.5% of flowClass A Common StockSEC:0001587739-25-000005:0
10,558 shares@ US$25.141.0% of flowClass A Common StockSEC:0001587739-25-000005:1
25 of 182 declarations
About Premier, Inc.
Premier, Inc. (ticker: PINC) is a United States-based healthcare company that has traded on the NASDAQ, placing it among the NYSE/NASDAQ-listed names followed by equity investors in the U.S. market. Headquartered in Charlotte, North Carolina, Premier describes itself as a technology-driven healthcare improvement company focused on helping providers lower costs, improve outcomes, and strengthen operational performance across the U.S. healthcare system. The company says it supports roughly two-thirds of U.S. healthcare providers, underscoring a broad national footprint and a meaningful role in hospital procurement and performance optimization. ([premierinc.com](https://premierinc.com/about?utm_source=openai))
Premier’s roots lie in the consolidation of healthcare alliances and purchasing organizations built to give hospitals more bargaining power and better access to supply-chain expertise. Over time, the company evolved beyond traditional group purchasing into a broader healthcare solutions platform. Its business model combines group purchasing organization services, supply-chain optimization, data and analytics, consulting, and clinical decision support tools. The company’s stated mission is to transform healthcare by helping providers improve quality while managing costs, a positioning that resonates with large hospital systems facing inflationary purchasing pressures, labor constraints, and the need for better evidence-based decision-making. ([premierinc.com](https://premierinc.com/about/why-premier?utm_source=openai))
Read moreShow less
Premier’s principal operating areas are Supply Chain Services and Performance Services. Supply Chain Services includes sourcing, contract administration, digital supply-chain solutions, and co-management programs that support provider and supplier relationships. Performance Services includes analytics, consulting, and software-enabled clinical support capabilities. Premier has also continued to invest in its technology stack; in 2025 it acquired IllumiCare to expand clinical decision support capabilities, with the acquired solution being marketed under the Stanson Health brand. That move reinforced Premier’s strategy of combining procurement scale with software and data tools rather than relying solely on a membership-driven GPO model. ([investors.premierinc.com](https://investors.premierinc.com/news/news-details/2025/Premier-Inc--Expands-Clinical-Decision-Support-CDS-Capabilities-with-Acquisition-of-IllumiCare/default.aspx?utm_source=openai))
The company has a long-standing position in U.S. healthcare supply chain management, with relationships spanning hospitals, health systems, manufacturers, and distributors. Recent commercial activity also shows that Premier continues to use its platform to secure critical products and expand into ambulatory and specialty-care channels. In 2025, Premier launched a $200 million accelerated share repurchase program, then later announced a definitive agreement to be acquired by Patient Square Capital for $2.6 billion; the transaction was completed in November 2025. In May 2026, Premier also announced Emad Rizk, M.D. as CEO, President, and Chairman. For investors, this creates a profile of a U.S.-listed healthcare services and technology platform whose near-term narrative has been shaped by strategic actions, M&A, and a transition away from the public-market setup. ([investors.premierinc.com](https://investors.premierinc.com/news/news-details/2025/Premier-Inc.-Enters-Into-200-Million-Accelerated-Share-Repurchase-Program/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
